ThymoTropin™ – The First Natural Myostatin Regulator

Veos Pharmaceuticals, SL

Powering the Future of Muscle Health & Performance

Dr. Bassam Damaj | bdamaj@veospharma.com | www.veospharma.com

GROWTH TRACTION & GLOCAL COMMERCIAL VALIDATION

WHO WE ARE

- Veos Pharma pioneers myostatin and TRPV3 activation for muscle preservation.
- We partner with global leaders to commercialize science-backed function health innovations.
- Cap Table: 2 co-founders

FINANCIAL STRENGTH

Founded in 2022, profitable in 2024, Projected to exceed €1M in revenue in 2025, with a 97% CAGR across product lines (OTC, functional ingredients and biotech)

GLOBAL RECOGNITION

- Engaged in licensing discussions with Nestle, J&J, Abbott and Hitashi
- Recognized by MassChallenge, Johnon & Johnson QuickFire

INTELLECTUAL PROPERTY

- Patents granted in US, EU, CA, PT
- Coverage for composition of matter and use of ThymoTropin
- Protection though 2040

EXIT STRATEGY 2027-2029:

- Strategic acquisition by a global nutrition, pharma, or consumer health leader seeking IP-protected muscle health innovation
- Regional licensing deals for EU (with focus on DACH, Nordics), and APAC through clinically validated ingredient positioning
- Series A financing to expand commercial operations and launch new indications (e.g., oncology, metabolic health)
- Dual-path IPO or M&A readiness once the business surpasses €10M revenue run rate with validated partnerships



Contributing to 3 Sustainable Development Goals:

- **SDG 3 – Health & Well-being**
- **SDG 9 – Industry & Innovation**
- **SDG 12 – Responsible Consumption & Production**

VEOS PHARMACEUTICALS

ThymoTropin MUSCLE HEALTH

ThymoTropin™ – A First-in-Class Innovation Targeting the Root Cause of Muscle Loss

WHAT MAKES IT RADICAL

FIRST & ONLY TRPV3/MYOSTATIN REGULATOR

- Regulates myostatin, a master negative regulator of muscle growth — no protein or amino acid supplement addresses this mechanism.
- Activates TRPV3 ion channels, triggering calcium influx, mitochondrial stimulation, and anabolic signaling.
- Natural, plant-based, non-hormonal – unlike anything in current sports nutrition, aging, or GLP-1 segments.
- Effective at low dose, without calories, sugar, or protein — radically different from Boost, Ensure, whey

CLINICAL DIFFERENTIATION

VALIDATED MECHANISTIC ADVANTAGE

- ↓ 36.2% myostatin (human study) → targets root cause
- ↑ 17.6% strength
- ↑ 9.6% muscle size (arm circumference)
- Outperforms standard amino or whey-based regimens

Risk	Risk Level	Mitigation Strategy
Novel Mechanism (TRPV3 + Myostatin)	**High**	Human clinical study complete (↓36.2% myostatin, ↑17.6% strength); mechanism confirmed in humans
Regulatory Uncertainty (EU/FFC)	**Moderate**	Launch via Article 13.1 with muscle claim; EFSA 13.5 dossier prep underway; Canada NHP already approved & commercial
Market Education (new category vs protein)	**Moderate**	Partnering with Nestlé, Hitachi for co-branding + pilot launches targeting GLP-1 & aging markets
Formulation Scaling / Ingredient Supply	**Low**	GMP supply chain in place; product validated under StroVia™ (stable, shelf-ready capsule form)
Partner Filing Dependence (e.g. FFC in Japan)	**Moderate**	Engaged with local regulatory consultants and distributors in Japan and EU to secure fallback options



Unlike Amino Acid, Protein, Or Hormone-based Products, Thymotropin™ Is The First To Activate TRPV3 While Clinically Lowering Myostatin In Humans

VEOS PHARMACEUTICALS

ThymoTropin MUSCLE HEALTH

ThymoTropin™ – Pre-Clinica, Clinical & Consumer Validation Summary

IN VITRO & MICE DATA

PRE-CLINICAL DATA

- +94% increase in muscle fiber width
- +7% increase in quadriceps mass
- +25% increase in pectoralis muscle mass
- +0.7°C increase in upper & lower body temperature (p = 0.001)
- +37% improvement in running time

HUMAN CLINICAL DATA

STUDY DESIGN

- Open-Label clinical stay (N=20, adults aged >50)
- Duration: 60 days
- Dosage: 60 days
- Location: USA

KEY CLINICAL RESULTS

Primary Outcomes

- 36.2% reduction in serum myostatin levels (P=0.046)
- 17.6% increase in strength
- 9.6% increase in right arm circumference

CONSUMER FEEDBACK

Global Assessment Questionnaire

- 94% would recommend ThymoTropin to others
- 82% would continue using ThymoTropin

Based on clinical trials & real-word use and follow-up survey in Canada launch (over 2000 units distributed and tracked

SAFETY & TOLERABILITY

- No serious adverse events
- One mild, transient report of bloating

VEOS PHARMACEUTICALS

ThymoTropin MUSCLE HEALTH

ThymoTropin™: Market Opportunity & Unmet Medical Need

MARKET OPPORTUNITY





ThymoTropin not only addresses this growing market but also intersects with health and wealth by preserving muscle health, which is vital for reducing healthcare costs and enhancing financial stability

Preventing muscle atrophy can significantly lower long-term healthcare expenses, making ThymoTropin an essential component in modern wellness programs

VEOS PHARMACEUTICALS

ThymoTropin MUSCLE HEALTH

Scalable B2B Model for Global Launch Partnerships

VEOS PHARMA PROVIDES

→ Ingredient supply (GMP)

→ Clinical & preclinical data

→ Regulatory package (EFSA, GRAS, FFC-ready)

→ IP License

PARTNER PROVIDES

→ Brand ownership, product formulation & commercialization strategy

→ Market-specific regulatory submission (e.g., FFC, EFSA/FSD, NHP)

→ Distribution access and/or co-development execution

→ Marketing via licensing + co-branded launches with region-specific partners (e.g., Hitachi, Nestlé) and DTC through established platforms

TOGETHER

→ Commercialize a clinically supported sarcopenia solution leveraging ThymoTropin™'s mechanism of action

→ Align with public health priorities in aging and GLP-1-related muscle loss

Examples: Nestlé, J&J, Unilever, Abbott, Hitachi Healthcare

VEOS PHARMACEUTICALS

ThymoTropin MUSCLE HEALTH

ThymoTropin™ vs. Competitors – A Unique Mechanism for Muscle Preservation

Brand	Market Focus	Limitations	ThymoTropin™ Advantage
Abbott Protality	Weight loss, muscle support	Requires large liquid intake, bloating risk	Tablet form, avoids bloating, targets myostatin directly
Nestlé Boost	Caloric/protein combo	High calories; not optimized for lean preservation	Myostatin regulation with lean mass preservation
Whey Protein	Athletes, fitness	Generic BCAA path, not mechanism-based	Targets TRPV3 + Myostatin; stronger anabolic response
Ensure	Seniors, general nutrition	High sugar/calories; non-specific	Low-calorie, muscle-specific, aging-friendly formulation

Sustainable Competitive Advantage

ThymoTropin™ is uniquely defensible due to:

- Patent protection through 2040 in US, EU, CA, and PCT — covering both composition and use
- Mechanism-level innovation (TRPV3 activation + myostatin reduction) not reproducible by protein, amino acids, or caloric supplements
- Clinically validated in humans — not just in vitro or theoretical
- Low-dose, plant-based format ideal for clean-label markets and EFSA/FFC/NHP pathways
- Scalable ingredient licensing model ensures partner exclusivity and market protection

ThymoTropin™ is the first plant-based, low-calorie solution clinically shown to reduce myostatin and increase strength in humans. Unlike protein supplements, it works at the mechanism level, not just macronutrient substitution

VEOS PHARMACEUTICALS

ThymoTropin MUSCLE HEALTH

OUR TEAM – JAPAN EXPERTISE DRIVING INNOVATION

Our leadership brings together deep regulatory, commercial, and scientific experience:

- ✓ I personally worked at Mitsubishi Tanabe for nearly two years, leading anti-inflammation and cachexia programs.
- ✓ Our team has successfully partnered with Japanese companies and understands the importance of long-term relationships, reliability, and regulatory trust.
- ✓ We've built and exited companies across the U.S., EU, and Japan — and we're ready to do the same with ThymoTropin™

Dr. Bassam Damaj – President & CO-Founder
Biotech Entrepreneur & Pharma Pioneer
- 7 Companies Founded, 3 IPOs, $1B+ in Partnerships
- Raised $500M+ Across US, EU, & MENA
- Former Leadership: Pfizer, Genentech, Mitsubishi Tanabe

Samira Wifak, MA, CB – CFO & CO-Founder
Finance & Growth Strategist
- CEO of R&D Healthcare ($80M+ Revenue)
- Oversees Financial Strategy & Expansion

Ysabella Fernando, RAC – Head of Regulatory Affairs
- 60+ Product Approvals Worldwide
- Regulatory Expert: GRAS, EFSA, Health Canada

Rajan Sah, MD, PhD - Consultant
- Inventor of ThymoTropin and an expert in muscle health and myostatin regulation
- Professor of Internal Medicine, Cardiovascular Division &Professor of Cell Biology and Physiology at the Washington University in St. Louis

Max Sasanchyn – Head of E-Com. & Digital Growth
- Led Amazon & Direct Sales Expansion
- Scaled Veos Pharma's Online Market Presence